A bilaterally blind patient in Israel is the first recipient of an artificial cornea developed by CorNeat Vision. The 78-year-old patient was able to read and recognize family members following the procedure.

The implant consists of an optical component attached to a biocompatible material that resembles the human extracellular matrix. The nonbiodegradable material provides both the physical structure and biochemical The implant consists of an optical component attached to a biocompatible material that resembles the human extracellular matrix. Source: CorNeat Visionsignals to support fibroblast viability and fuse with nearby native tissues.

The CorNeat KPro implant is designed to replace deformed, scarred or opacified corneas and is expected to fully and immediately rehabilitate the vision of corneally blind patients following a relatively simple implantation procedure. The synthetic cornea is one of the first applications for CorNeat’s material, and it could have other significant applications in tissue repair and for the implantation of medical sensors and internal devices.

The successful implantation is the first step in a multi-national clinical trial, geared toward attaining the CE Mark, U.S. Food and Drug Administration clearance and China National Medical Products Administration approval.